Spark Therapeutics Inc (NASDAQ:ONCE) – Wedbush lifted their Q4 2017 earnings estimates for Spark Therapeutics in a report issued on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings per share of ($1.58) for the quarter, up from their prior forecast of ($1.71). Wedbush currently has a “Neutral” rating and a $50.00 price target on the stock. Wedbush also issued estimates for Spark Therapeutics’ Q1 2018 earnings at ($1.80) EPS, Q2 2018 earnings at ($1.76) EPS, Q3 2018 earnings at ($1.74) EPS, Q4 2018 earnings at ($1.69) EPS, FY2018 earnings at ($6.99) EPS, FY2019 earnings at ($5.32) EPS, FY2020 earnings at ($2.77) EPS and FY2021 earnings at $0.73 EPS.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period last year, the business posted ($1.07) earnings per share. The firm’s quarterly revenue was up 45.8% on a year-over-year basis.

A number of other research analysts have also weighed in on the stock. BMO Capital Markets set a $89.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 10th. Cowen reissued a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Jefferies Group reissued a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Cantor Fitzgerald reissued a “buy” rating and set a $105.00 price target (up from $94.00) on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group reissued a “buy” rating and set a $111.00 price target on shares of Spark Therapeutics in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $76.19.

Spark Therapeutics (ONCE) opened at $46.37 on Friday. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Belpointe Asset Management LLC purchased a new position in shares of Spark Therapeutics in the third quarter worth about $403,000. Neuberger Berman Group LLC purchased a new position in shares of Spark Therapeutics in the third quarter worth about $672,000. Cubist Systematic Strategies LLC increased its stake in shares of Spark Therapeutics by 257.7% in the third quarter. Cubist Systematic Strategies LLC now owns 8,588 shares of the biotechnology company’s stock worth $766,000 after purchasing an additional 6,187 shares in the last quarter. Perceptive Advisors LLC purchased a new position in shares of Spark Therapeutics in the third quarter worth about $16,049,000. Finally, Orbimed Advisors LLC purchased a new position in shares of Spark Therapeutics in the third quarter worth about $38,340,000. Hedge funds and other institutional investors own 94.94% of the company’s stock.

In other news, Director Hospital Of Philade Children’s sold 1,000,000 shares of Spark Therapeutics stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $84.63, for a total value of $84,630,000.00. Following the completion of the transaction, the director now owns 3,928,707 shares in the company, valued at $332,486,473.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the transaction, the insider now owns 215,000 shares of the company’s stock, valued at approximately $15,333,800. The disclosure for this sale can be found here. Insiders have sold 1,068,809 shares of company stock valued at $89,809,385 in the last 90 days. 7.30% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Wedbush Research Analysts Lift Earnings Estimates for Spark Therapeutics Inc (ONCE)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/16/wedbush-research-analysts-lift-earnings-estimates-for-spark-therapeutics-inc-once.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Stock Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related stocks with our FREE daily email newsletter.